Adverse neurological outcome is a major cause of long-term morbidity in ex-preterm children. To investigate the effect of parturition and inflammation on the fetal brain, we utilized two in vivo mouse models of preterm birth. To mimic the most common human scenario of preterm birth, we used a mouse model of intrauterine inflammation by intrauterine infusion of lipopolysaccharide (LPS). To investigate the effect of parturition on the immature fetal brain, in the absence of inflammation, we used a non-infectious model of preterm birth by administering RU486. Pro-inflammatory cytokines (IL-10, IL-1β, IL-6 and TNF-α) in amniotic fluid and inflammatory biomarkers in maternal serum and amniotic fluid were compared between the two models using ELISA. Pro-inflammatory cytokine expression was evaluated in the whole fetal brains from the two models. Primary neuronal cultures from the fetal cortex were established from the different models and controls in order to compare the neuronal morphology. Only the intrauterine inflammation model resulted in an elevation of inflammatory biomarkers in the maternal serum and amniotic fluid. Exposure to inflammationinduced preterm birth, but not non-infectious preterm birth, also resulted in an increase in cytokine mRNA in whole fetal brain and in disrupted fetal neuronal morphology. In particular, Microtubuleassociated protein 2 (MAP2) staining was decreased and the number of dendrites was reduced (P < 0.001, ANOVA between groups). These results suggest that inflammation-induced preterm birth and not the process of preterm birth may result in neuroinflammation and alter fetal neuronal morphology. Keywords mouse model of preterm birth; neuroinflammation; neuronal injuryIn the United States, approximately 12% of all live births are delivered preterm (Green et al., 2005). Preterm birth (PTB) is the leading cause of neonatal mortality and morbidity in the NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptUnited States. Specifically, PTB is a risk factor for adverse neurological outcome for expreterm children (Anderson and Doyle, 2003;Hack et al., 2005).It has long been believed that cerebral palsy is the primary neurological outcome of clinical interest. However, it is now known that ex-preterm children also are at a significant risk for a spectrum of cognitive and neurobehavioral disorders Wood et al., 2005;Costeloe, 2006;Limperopoulos et al., 2007;Lindstrom et al., 2009) including autism spectrum disorders (Brimacombe et al., 2007;Limperopoulos et al., 2008;Schendel and Bhasin, 2008). Current understanding of the pathogenesis of fetal brain injury in a PTB focuses mainly on specific structural findings of white matter damage (WMD) (Cai et al., 2000;Paintlia et al., 2004;Rousset et al., 2006). This current paradigm may be insufficient to explain the increasing prevalence of adverse cognitive and neurobehavioral outcomes in ex-preterm infants.While adverse neurological outcomes are increasingly prevalent in ex-preterm children, it remains unknown whether th...

Objective-To elucidate possible mechanisms of fetal neuronal injury in inflammation-induced preterm birth.Study design-Utilizing mouse model of preterm birth, primary cultures were prepared from fetal brains: 1) control neurons (CN); 2) LPS-exposed neurons (LN); 3) control co-culture (CCC), consisting of neurons and glia; 4) LPS-exposed co-culture (LCC), consisting of LPS-exposed neurons and glia. CN and LN were treated with culture media from CN, LN, CCC and LCC after 24 hours in vitro. Immunocytochemistry was performed for culture characterization and neuronal morphology. Quantitative PCR was performed for neuronal differentiation marker, MAP2, and for cell death mediators, Caspases 1, 3 and 9.Results-LPS exposure in vivo did not influence neuronal or glial content in co-cultures but decreased expression of MAP2 in LN. Media from LN and LCC induced morphological changes in control neurons comparable to LN. The neuronal damage caused by in vivo exposure (LN) could not be reversed by media from control groups.Conclusion-LPS-induced preterm birth may be responsible for irreversible neuronal injury.

Using a radioligand binding assay we have demonstrated that phosphacan, a chondroitin sulfate proteoglycan of nervous tissue that also represents the extracellular domain of a receptor-type protein tyrosine phosphatase, shows saturable, reversible, high-affinity binding (K d ϳ6 nM) to fibroblast growth factor-2 (FGF-2). Binding was reduced by only ϳ35% following chondroitinase treatment of the proteoglycan, indicating that the interaction is mediated primarily through the core protein rather than the glycosaminoglycan chains. Immunocytochemical studies also showed an overlapping localization of FGF-2 and phosphacan in the developing central nervous system. At concentrations of 10 g protein/ml, both native phosphacan and the core protein obtained by chondroitinase treatment potentiated the mitogenic effect of FGF-2 (5 ng/ml) on NIH/3T3 cells by 75-90%, which is nearly the same potentiation as that produced by heparin at an equivalent concentration. Although studies on the role of proteoglycans in mediating the binding and mitogenic effects of FGF-2 have previously focused on cell surface heparan sulfate, our results indicate that the core protein of a chondroitin sulfate proteoglycan may also regulate the access of FGF-2 to cell surface signaling receptors in nervous tissue.Phosphacan and neurocan are nervous tissue-specific chondroitin sulfate proteoglycans that are high-affinity ligands of several immunoglobulin superfamily neural cell adhesion molecules and of the extracellular matrix proteins tenascin-C and tenascin-R (1-3). These interactions are variously mediated by the chondroitin sulfate chains, N-linked oligosaccharides present on the core glycoproteins, or by other structural features of the proteoglycans that have not yet been specifically identified. Phosphacan and neurocan both bind to neurons and have potent inhibitory effects on cell adhesion and neurite outgrowth, although in certain experimental situations phosphacan may also stimulate neurite growth. Neurocan is synthesized by neurons and is a member of the family of hyaluronan-binding chondroitin sulfate proteoglycans that also includes aggrecan, versican, and brevican, whereas phosphacan, which is produced by astrocytes, is an alternative splicing product representing the extracellular domain of a receptor-type protein tyrosine phosphatase. Phosphacan is also a ligand of the neural differentiation factor HB-GAM 1 (heparin-binding growth-associated molecule)/pleiotrophin (3, 4), and both neurocan and phosphacan bind with high affinity to HB-GAM and to the related differentiation factor amphoterin, with which they colocalize in nervous tissue (3). The interactions with HB-GAM and amphoterin are largely mediated by the chondroitin sulfate chains of the proteoglycans.

Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of HIV-positive individuals suffer from HIV-Associated Neurocognitive Disorders (HAND). Studies of antiretroviral treated patients have revealed persistent white matter pathologies including diffuse myelin pallor, diminished white matter tracts, and decreased myelin protein mRNAs. Loss of myelin can contribute to neurocognitive dysfunction as the myelin membrane generated by oligodendrocytes is essential for rapid signal transduction and axonal maintenance. We hypothesized that myelin changes in HAND are partly due to effects of antiretroviral drugs on oligodendrocyte survival and/or maturation. We showed that primary mouse oligodendrocyte precursor cell cultures treated with therapeutic concentrations of HIV protease inhibitors Ritonavir or Lopinavir displayed dose-dependent decreases in oligodendrocyte maturation; however, this effect was rapidly reversed following drug removal. Conversely, nucleoside reverse transcriptase inhibitor Zidovudine had no effect. Furthermore, in vivo Ritonavir administration to adult mice reduced frontal cortex myelin protein levels. Finally, prefrontal cortex tissue from HIV-positive individuals with HAND on cART showed a significant decrease in myelin basic protein compared with untreated HIV-positive individuals with HAND or HIV-negative controls. These findings demonstrate that antiretrovirals can impact myelin integrity, and have implications for myelination in juvenile HIV patients, and myelin maintenance in adults on lifelong therapy.

Glutamate is an important regulator of dendrite development; however, during cerebral ischemia, massive glutamate release can lead to neurodegeneration and death. An early consequence of glutamate excitotoxicity is dendrite injury, which often precedes cell death. We examined the effect of glutamate on dendrite growth from embryonic day 18 (E18) mouse cortical neurons grown for 3 days in vitro (DIV) and immunolabeled with anti-microtubule-associated protein (MAP)2 and anti-neurofilament (NF)-H, to identify dendrites and axons, respectively. Cortical neurons exposed to excess extracellular glutamate (100 microM) displayed reduced dendrite growth, which occurred in the absence of cell death. This effect was mimicked by the ionotropic glutamate receptor agonist N-methyl-D-aspartate (NMDA) and blocked by the ionotropic glutamate receptor antagonist kynurenic acid and the NMDA receptor-specific antagonist MK-801. The non-NMDA receptor agonist AMPA, however, did not affect process growth. Neither NMDA nor AMPA influenced neuron survival. Immunolabeling and Western blot analysis of NMDA receptors using antibodies against the NR1 subunit, demonstrated that immature cortical neurons used in this study, express NMDA receptors. These results suggest that excess glutamate decreases dendrite growth through a mechanism resulting from NMDA receptor subclass activation. Furthermore, these data support the possibility that excess glutamate activation of NMDA receptors mediate both cell death in mature neurons and the inhibitory effect of excess glutamate on dendrite growth in immature neurons or in the absence of cell death.

No abstract

SCO-spondin is a newly identified protein, strongly expressed in the subcommissural organ (SCO), an ependymal differentiation of the brain. When secreted into the cerebrospinal fluid at the entrance to the Sylvian aqueduct, it condenses and forms Reissner's fiber. Several conserved domains have previously been characterizedin SCO-spondin, e.g., thrombospondin type 1 repeats (TSRs), low-density lipoprotein receptor (LDLr) type A repeats, and epidermal-growth-factor-like domains, which are potent sites of protein-protein interaction. To clarify the role of this protein on neuronal development, we have tested the effect of oligopeptides, the sequences of which include highly conserved amino acids of TSRs, LDLr type A repeats and a potent site of attachment to proteoglycan, on cortical and spinal-cord neurons in primary cell cultures. One of these peptides (WSGWSSCSRSCG), corresponding to a SCO-spondin TSR sequence, markedly increases adhesivity and neuritic outgrowth of cortical neurons and induces an opposite effect on cortical and spinal-cord neuronal aggregation. These effects are specific, as no response is observed with the scrambled sequence of this peptide. Another peptide (WGPCSVSCG) is only slightly active on adhesivity and neuritic outgrowth of cortical neurons and has no effect on spinal-cord neurons. Peptides derived from other conserved domains of SCO-spondin are not effective under our experimental conditions. Thus, SCO-spondin may be responsible for at least a part of the effects previously observed on neuronal cells cultured in the presence of Reissner's fiber. In addition, SCO-spondin seems to interfere with neuronal development and/or axonal guidance during ontogenesis of the central nervous system in modulating side-to-side interactions and neuritic outgrowth.

Reissner's fibre is the condensed form of glycoproteins secreted by the subcommissural organ; it extends through the central canal to the caudal end of the spinal cord. The effect of Reissner's fibre was assessed on dissociated embryonic chick cortical neuronal cells grown in chemically defined medium, by using two cell culture systems: (1) low-density cultures, in which neuronal cells remained evenly distributed; (2) high-density cultures, in which neuronal cells aggregated, displaying prominent neuritic outgrowth. Reissner's fibre, when added to low-density cultures, induced neuronal aggregation and neuritic outgrowth but this effect was restricted to an area centred around Reissner's fibre. Reissner's fibre, when added to high-density cultures, potentiated cell aggregation. Antibodies inhibiting the neural cell adhesion molecule or N-cadherin, and soluble Reissner's fibre material (reported previously to have anti-aggregative activity), did not prevent the aggregative activity induced by Reissner's fibre. Neuronal cells showed a similar reaction pattern when heparin or Reissner's fibre was added to the culture. These results suggest that the subcommissural organ/Reissner's fibre complex has multifunctional activities and may modulate cell-cell interactions during the development of the central nervous system.